Targeting hypoxia downstream signaling protein, CAIX, for CAR T-cell therapy against glioblastoma
Jing Cui(National Institutes of Health), Zhuang Zhengping(National Institutes of Health), Dongqing Cao(Fudan University), Herui Wang(National Institute of Neurological Disorders and Stroke), Yu Yao(Qinghai University), Pauline Dmitriev(National Institute of Neurological Disorders and Stroke), Chunxia Ji(Shanghai Public Health Clinical Center), Qi Song(Sun Yat-sen University), Xiaoyu Cao(Chengdu University of Traditional Chinese Medicine), Mark R. Gilbert(Johns Hopkins University SAIS Bologna Center), Mitchell Sun(National Institutes of Health), Iris H. Indig(National Institutes of Health), Yang Wang(Hubei University of Technology), Qi Zhang(Xuzhou Medical College), Kaiyong Yang(Nanjing University of Chinese Medicine), Liemei Guo(Renji Hospital), Jared S. Rosenblum(National Institutes of Health)
Cited by 72
Related Papers
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
|Neuro-Oncology|2020|1.1k
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
|Journal of Clinical Oncology|2013|1.1k
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
|New England Journal of Medicine|2016|1k
Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001
|Journal of Clinical Oncology|2020|827